<DOC>
	<DOCNO>NCT01744288</DOCNO>
	<brief_summary>Study see platelet transfusion stop lessen effect drug platelet</brief_summary>
	<brief_title>Study See Platelet Transfusion Stop Lessen Effect Drug Platelets</brief_title>
	<detailed_description>A open label , randomize , crossover potential parallel , single dose study ticagrelor 180 mg acetylsalicylic acid ( ASA ) healthy volunteer follow autologous vivo platelet transfusion determine effect platelet supplementation reversibility platelet inhibition</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy male and/or female volunteer age 18 50 year , inclusive , suitable vein cannulation repeat venipuncture . ( Healthy determine medical history physical examination , laboratory parameter , electrocardiogram ( ECG ) perform Have body mass index ( BMI ) 18 35 kg/m2 ( inclusive ) weigh least 50 kg 120 kg ADP induce platelet aggregation &lt; 60 % prior platelet apheresis History peptic ulcer disease Healthy volunteer propensity bleed ( eg , due recent trauma , recent surgery , active recent gastrointestinal bleeding moderate hepatic impairment ) Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product Current smoker , smoke use nicotine product within previous 3 month test positive cotinine screen admission study center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Phase 1 Safety ,</keyword>
	<keyword>pharmacodynamic ,</keyword>
	<keyword>Ticagrelor ,</keyword>
	<keyword>Clopidogrel ,</keyword>
	<keyword>Platelets</keyword>
</DOC>